Agonist-induced activation of the S1P receptor 2 constitutes a novel osteoanabolic therapy for the treatment of osteoporosis in mice.
Weske S, Vaidya M, von Wnuck Lipinski K, Keul P, Manthe K, Burkhart C, Haberhauer G, Heusch G, Levkau B.
Bone. 2019 Aug;125:1-7. doi: 10.1016/j.bone.2019.04.015. Epub 2019 Apr 24.

Regulation of ABCA1-mediated cholesterol efflux by sphingosine-1-phosphate signaling in macrophages.
Vaidya M, Jentsch JA, Peters S, Keul P, Weske S, Gräler MH, Mladenov E, Iliakis G, Heusch G, Levkau B.
J Lipid Res. 2019 Mar;60(3):506-515. doi: 10.1194/jlr.M088443. Epub 2019 Jan 17.

Potent anti-inflammatory properties of HDL in vascular smooth muscle cells mediated by HDL-S1P and their impairment in coronary artery disease due to lower HDL-S1P: a new aspect of HDL dysfunction and its therapy.
Keul P, Polzin A, Kaiser K, Gräler M, Dannenberg L, Daum G, Heusch G, Levkau B.
FASEB J. 2019 Jan;33(1):1482-1495. doi: 10.1096/fj.201801245R. Epub 2018 Aug 21.

Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss.
Weske S, Vaidya M, Reese A, von Wnuck Lipinski K, Keul P, Bayer JK, Fischer JW, Flögel U, Nelsen J, Epple M, Scatena M, Schwedhelm E, Dörr M, Völzke H, Moritz E, Hannemann A, Rauch BH, Gräler MH, Heusch G, Levkau B.
Nat Med. 2018 May;24(5):667-678. doi: 10.1038/s41591-018-0005-y. Epub 2018 Apr 16.

Hepatocyte nuclear factor 1A deficiency causes hemolytic anemia in mice by altering erythrocyte sphingolipid homeostasis.
von Wnuck Lipinski K, Weske S, Keul P, Peters S, Baba HA, Heusch G, Gräler MH, Levkau B.
Blood. 2017 Dec 21;130(25):2786-2798. doi: 10.1182/blood-2017-03-774356. Epub 2017 Nov 6

Hepatocyte Nuclear Factor 1A Is a Cell-Intrinsic Transcription Factor Required for B Cell Differentiation and Development in Mice.
von Wnuck Lipinski K, Sattler K, Peters S, Weske S, Keul P, Klump H, Heusch G, Göthert JR, Levkau B.         
J Immunol. 2016 Feb 15;196(4):1655-65. doi: 10.4049/jimmunol.1500897. Epub 2016 Jan 22.

Sphingosine-1-Phosphate Receptor 1 Regulates Cardiac Function by Modulating Ca2+ Sensitivity and Na+/H+ Exchange and Mediates Protection by Ischemic Preconditioning.
Keul P, van Borren MM, Ghanem A, Müller FU, Baartscheer A, Verkerk AO, Stümpel F, Schulte JS, Hamdani N, Linke WA, van Loenen P, Matus M, Schmitz W, Stypmann J, Tiemann K, Ravesloot JH, Alewijnse AE, Hermann S, Spijkers LJ, Hiller KH, Herr D, Heusch G, Schäfers M, Peters SL, Chun J, Levkau B.
J Am Heart Assoc. 2016 May 20;5(5):e003393. doi: 10.1161/JAHA.116.003393.

Defects of High-Density Lipoproteins in Coronary Artery Disease Caused by Low Sphingosine-1-Phosphate Content: Correction by Sphingosine-1-Phosphate-Loading.    
Sattler K, Gräler M, Keul P, Weske S, Reimann CM, Jindrová H, Kleinbongard P, Sabbadini R, Bröcker-Preuss M, Erbel R, Heusch G, Levkau B.
J Am Coll Cardiol. 2015 Sep 29;66(13):1470-85. doi: 10.1016/j.jacc.2015.07.057

Sphingosine-1-phosphate receptor 3 promotes leukocyte rolling by mobilizing endothelial P-selectin.
Nussbaum C, Bannenberg S, Keul P, Gräler MH, Gonçalves-de-Albuquerque CF, Korhonen H, von Wnuck Lipinski K, Heusch G, de Castro Faria Neto HC, Rohwedder I, Göthert JR, Prasad VP, Haufe G, Lange-Sperandio B, Offermanns S, Sperandio M, Levkau B.
Nat Commun. 2015 Apr 2;6:6416. doi: 10.1038/ncomms7416.